TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03681990
Drug: 3M CHG/IPA Prep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically to intact skin
Study: NCT00174967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
Study: NCT00408148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undistinguishable placebo tablets
Study: NCT02666287
Drug: BAT/FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
Study: NCT01082588
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study: NCT01082588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study: NCT03490461
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
Study: NCT02327338
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg ibuprofen administered 400mg at 4 hour intervals
Study: NCT00318500
Drug: ERB-041
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01460498
Drug: Tyrosine kinase inhibitor (TKI)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of dose already receiving during previous 6 months.
Study: NCT02429388
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
Study: NCT03743103
Drug: Brevibloc, 10 Mg/mL Intravenous Solution
Normalized name: Brevibloc, 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/h every 5 minutes until reaching the pressure target
Study: NCT02942381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administrated 30 minutes before start of root canal treatment
Study: NCT00270361
Drug: usual long term cardiac medications
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04624958
Drug: R-DHAOx
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
Study: NCT02255032
Drug: 0.8 mg CLS-TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Study: NCT02458339
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
Study: NCT00402558
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
Study: NCT03592537
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
Study: NCT02989779
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01348308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks.
Study: NCT03696108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
Study: NCT02372799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02372799
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01456299
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.
Study: NCT01456299
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml.
Study: NCT01054300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ertugliflozin administered as a single dose
Study: NCT04867993
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg/36h
Study: NCT00707278
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
Study: NCT02777970
Drug: Tramadol Hydrochloride/Dexketoprofen Trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02777970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03776604
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy.
Study: NCT03663465
Drug: SGAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGAs tablet
Study: NCT02008214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching pentoxifylline dosage
Study: NCT00004474
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via IV over 60 minutes on Days -5 to -2
Study: NCT02310425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: he control group (group C) did not receive S. boulardii (nor other probiotics)
Study: NCT00087256
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02123953
Drug: TAK-438 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets
Study: NCT03244540
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Study: NCT00676312
Drug: PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00473070
Drug: Tobradex AF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04590534
Drug: Sildosin Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
Study: NCT01062503
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
Study: NCT02267772
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Acetaminophen
Study: NCT03681574
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
Study: NCT03681574
Drug: GABA 15mg/kg Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
Study: NCT02091986
Drug: Symbicort pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
Study: NCT02091986
Drug: Symbicort pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
Study: NCT03681574
Drug: GABA 30mg/kg Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
Study: NCT01744184
Drug: Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entonox arm
Study: NCT01033955
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
Study: NCT01033955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical appearing encapsulated placebo.
Study: NCT02701127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00462280
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04859582
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally BID on Days 1 to 14 Q3W
Study: NCT03785067
Drug: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule taken orally once daily for 36 months
Study: NCT03785067
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule taken orally once daily for 36 months
Study: NCT03783936
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/m2
Study: NCT03783936
Drug: 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
Study: NCT00824980
Drug: IP10.C8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP10.C8 Gel 1%
Study: NCT01208740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill three times daily
Study: NCT00187330
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00474045
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study: NCT02839343
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
Study: NCT02839343
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin IV, leucovorin IV and 5-FU IV
Study: NCT01915576
Drug: BAY1125976
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
Study: NCT01915576
Drug: BAY1125976
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
Study: NCT01915576
Drug: BAY1125976
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
Study: NCT00367965
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT00808639
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenously 30mg/m2 over 30 minutes
Study: NCT00808639
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously 30mg/ms over 15 minutes
Study: NCT03053063
Drug: Placebo to match SEL 6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT03053063
Drug: Placebo to match SEL 18 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT00020943
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
Study: NCT02890537
Drug: Core decompression/PREOB® implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Study: NCT02890537
Drug: Core decompression/BMC implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
Study: NCT00020943
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/sq m IVP Day 3, Tx 1\& 2
Study: NCT00020943
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
Study: NCT00020943
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
Study: NCT00661661
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BID up to 10 mg BID until launch
Study: NCT03002064
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
Study: NCT00489905
Drug: Zolderonic acid (Zometa)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01720498
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effect site concentration of remifentanil
Study: NCT03400176
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT03845582
Drug: ALK-001 oral capsule
Normalized name: ergot alkaloids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration for 24 months
Study: NCT03845582
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration for 24 months
Study: NCT02539576
Drug: ABC/DTG/3TC FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally.
Study: NCT04989127
Drug: Antibiotics, Penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics are prescribed for the patients.
Study: NCT01698918
Drug: Standard of care to treat stomatitis (Stomatitis sub-study)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
Study: NCT02844699
Drug: Mobilan (M-VM3)
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
Study: NCT02844699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% infusion solution of dextrose (glucose)
Study: NCT00859651
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT02409563
Drug: Budesonide nasal spray (50 mcg bid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151734
Drug: KALOMIN™ Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151734
Drug: Umckamin syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299285
Drug: LY3009104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00965341
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
Study: NCT00965341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
Study: NCT04756154
Drug: CHG/IPA Surgical skin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically to the inguinal region for 2 minutes
Study: NCT04756154
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically to the inguinal region for 2 minutes
Study: NCT00129922
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00129922
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00251082
Drug: continuous combined estradiol and dydrogesterone
Normalized name: dydrogesterone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
Study: NCT00251082
Drug: continuous combined estradiol and dydrogesterone
Normalized name: dydrogesterone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Mg Estradiol and 5 Mg Dydrogesterone
Study: NCT00251082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00963027
Drug: Treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
Study: NCT00454220
Drug: MRrhTSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 patients to 0.01 mg MRrhTSH + 131-I arm
Study: NCT00463827
Drug: matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01077739
Drug: fluorouracil (5FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard FOLFOX regimen
Study: NCT01077739
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard FOLFOX regimen
Study: NCT01077739
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard XELOX regimen
Study: NCT02824601
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
Study: NCT04413552
Drug: INDV-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
Study: NCT04413552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
Study: NCT01790828
Drug: Xyntha : coagulation factor IIIV (recombinant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xyntha will be administered according to physician's discretion.
Study: NCT00877071
Drug: LC Bead loaded with doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
Study: NCT00264069
Drug: antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT00264069
Drug: antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT01275755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01275755
Drug: ADL5945 0.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02544464
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline) is administered after anesthesia induction
Study: NCT04098406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was liquid with identical color and taste
Study: NCT04680598
Drug: Antiviral Prophylaxis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
Study: NCT00102141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given as tablets orally once daily in the morning for 8 weeks